Regenerative Medicine Market Size, Share & Trends Report

Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category (Cardiovascular, Oncology), And Segment Forecasts, 2021 - 2027

  • Report ID: GVR-1-68038-952-4
  • Number of Pages: 273
  • Format: Electronic (PDF)
  • Historical Range: 2018 - 2019
  • Industry: Healthcare

Table Of Contents

Chapter 1 Executive Summary
                  1.1 Market Outlook
                  1.2 Competitive Milieu
                  1.3 Segment Outlook
                  1.4 Market Summary
Chapter 2 Research Methodology
                  2.1 Information Procurement
                  2.2 Information or Data Analysis
                  2.3 Market Scope & Definition
                      2.3.1 Product
                          2.3.1.1 Therapeutics
                          2.3.1.2 Tools
                          2.3.1.3 Banks
                          2.3.1.4 Services
                  2.4 Market Model
                      2.4.1 Historic and base year estimates
                      2.4.2 Forecast analysis
Chapter 3 Market Variables, Trends, & Scope
                  3.1 Market Lineage Outlook
                      3.1.1 Parent Market Outlook
                      3.1.2 Related/Ancillary Market Outlook
                  3.2 Market Dynamics
                      3.2.1 Market Driver Analysis
                          3.2.1.1 Presence of a strong pipeline and a large number of clinical trials
                          3.2.1.2 High economic impact of regenerative medicine
                          3.2.1.3 Emerging applications of gene therapy in regenerative medicine
                          3.2.1.4 Increasing government & private funding to support the development of regenerative medicine
                          3.2.1.5 Technological advancements in regenerative medicine (stem cell, tissue engineering, and nanotechnology)
                          3.2.1.6 Increase in strategic partnerships to accelerate development & commercialization of regenerative medicines
                          3.2.1.7 Rising prevalence of chronic diseases & genetic disorders, degenerative diseases, and bone & joint diseases leading to rise in demand for regenerative treatments
                      3.2.2 Market Restraint Analysis
                          3.2.3.1 High cost of treatment
                          3.2.3.2 Regulatory issues pertaining to stem cells, tissues engineering, and regenerative medicines
                  3.3 Market Challenge Analysis
                      3.3.1 Current challenges of on-market gene therapies
                  3.4 Penetration & Growth Prospect Mapping for Therapeutic Category, 2020
                  3.5 Reimbursement Framework
                      3.5.1 Reimbursement Framework & Clinical Translation of RM
                      3.5.2 Reimbursement Framework for RM: Europe
                      3.5.3 Reimbursement Framework for RM: South Korea
                  3.6 Technology Overview
                      3.6.1 Autologous Cell Transplantation
                      3.6.2 Next-Generation Cell-Based Therapies
                      3.6.3 CAR-T Cell Technologies
                  3.7 Cost Structure Analysis
                  3.8 User Perspective Analysis
                      3.8.1 Market Influencer Analysis
                      3.8.2 Consumer Behavior Analysis
                  3.9 Regenerative Medicine Market - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
                  3.10 Industry Analysis - Porter’s
                  3.11 Regenerative Medicine Market Analysis Tools
                      3.11.1 Major Deals & Strategic Alliances Analysis
                      3.11.2 Merger & Acquisition Deals
                      3.11.3 Collaboration & Partnerships
                      3.11.4 Business Expansion
                      3.11.5 Market Entry Strategies
                          3.11.5.1 Pharmaceutical and biotechnology companies
                          3.11.5.2 Raw material supplier
                          3.11.5.3 Contract Service Provider
                          3.11.5.4 Distributor
                          3.11.5.5 Companion Diagnostics companies:
                      3.11.6 Case Studies
                          3.11.6.1 MACI (Vericel Corporation):
                          3.11.6.2 LAVIV (Azficel-T) (Fibrocell Technologies):
Chapter 4 Competitive Analysis
                  4.1 Recent Developments & Impact Analysis, by Key Market Participants
                  4.2 Company/Competition Categorization
                  4.3 Vendor Landscape
                      4.3.1 List Of Key Distributors And Channel Partners
                      4.3.2 Key Customers
                      4.3.3 Key Company Market Position Analysis, 2020
                  4.4 Public Companies
                      4.4.1 Company Market Position Analysis
                      4.4.2 Company Market Ranking By Region
                      4.4.3 Competitive Dashboard Analysis
                      4.4.4 Market Differentiators
                  4.5 Private Companies
                      4.5.1 List Of Key Emerging Companies
                      4.5.2 Company Market Position Analysis
                      4.5.3 Regional Network Map
                      4.5.4 List Of Suppliers
                      4.5.5 Funding Outlook
                  4.6 Regenerative Medicine: Pipeline Analysis
                      4.6.1 Astellas Pharma Inc.
                      4.6.2 Bayer Ag
                      4.6.3 Astrazeneca
                      4.6.4 F. Hoffmann-La Roche Ltd
                      4.6.5 Pfizer Inc.
                      4.6.6 Merck & Co., Inc.
                      4.6.7 Abbott (St. Jude Children's Research Hospital)
                      4.6.8 Vericel Corporation
                      4.6.9 Novartis Ag
                      4.6.10 Glaxosmithkline Plc.
                      4.6.11 Baxter
                      4.6.12 Boehringer Ingelheim Gmbh
                      4.6.13 Amgen Inc.
                      4.6.14 Eli Lilly And Company
                      4.6.15 Bristol-Myers Squibb Company
                      4.6.16 Takara Bio Inc.
                      4.6.17 Vital Therapies, Inc. (Vtl)
                      4.6.18 Swedish Orphan Biovitrum
                      4.6.19 Stratatech Corporation (A Mallinckrodt Pharmaceuticals Company)
                      4.6.20 Stempeutics Research Pvt. Ltd
                      4.6.21 Soluble Systems, Llc
                      4.6.22 Smith & Nephew Plc
                      4.6.23 Shire Pharmaceuticals Group Plc
                      4.6.24 Beike Biotechnology Co., Ltd.
                      4.6.25 Sanbio, Inc.
                      4.6.26 ReNeuron Group Plc
                      4.6.27 Regeneus Ltd.
                      4.6.28 Regen Biopharma, Inc.
                      4.6.29 Q Therapeutics, Inc.
                      4.6.30 Promethera Biosciences
                      4.6.31 Pluristem Therapeutics, Inc. (PSTI)
                      4.6.32 Pharmicell Co., Ltd.
                      4.6.33 Osiris Therapeutics, Inc.
                      4.6.34 Orthofix International Nv
                      4.6.35 Orthocell Limited
                      4.6.36 Takeda Pharmaceutical Company Limited
                      4.6.37 Caladrius
                      4.6.38 U.S. Stem Cell Inc.
                      4.6.39 Cesca Therapeutics
                      4.6.40 Opex Therapeutics, Inc.
                      4.6.41 Northern Therapeutics, Inc.
                      4.6.42 Neuralstem Inc.
                      4.6.43 Multigene Vascular Systems, Inc.
                      4.6.44 Medipost Co. Ltd.
                      4.6.45 Mesoblast Ltd.
                      4.6.46 Macrocure Ltd. / Leap Therapeutics, Inc.
                      4.6.47 Living Cell Technologies, Ltd.
Chapter 5 Covid-19 Impact Analysis
                  5.1 COVID-19 Impact Analysis
                  5.2 Challenges Analysis
                      5.2.1 Manufacturing & Supply Challenges
                      5.2.2 Other Challenges
                  5.3 Opportunities analysis
                      5.3.1 Need For Development Of New Therapies Against SARS-COV-2
                          5.3.1.1 T-cell Therapy
                          5.3.1.2 Cell Therapy
                          5.3.1.3 Gene Therapy
                          5.3.1.4 Tissue engineering
                      5.3.2 Rise In Demand For Supply Chain Management Solutions
                  5.4 Challenges in Manufacturing T-cell Therapies Against COVID-19
                  5.5 Clinical Trial Analysis
                  5.6 Key Market Initiatives
                  5.7 Conclusion
Chapter 6 Regenerative Medicine Market: Product Business Analysis
                  6.1 Regenerative Medicine Market: Product Movement Analysis
                  6.2 Therapeutics
                      6.2.1 Global Regenerative Medicine Therapeutics Market, 2018 - 2027 (USD Million)
                      6.2.2 Primary Cell-Based Therapeutics
                          6.2.2.1 Global primary cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.2.2 Dermatology
                              6.2.2.2.1 Global dermatology primary cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.2.3 Musculoskeletal
                              6.2.2.3.1 Global musculoskeletal primary cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.2.4 Surgical
                              6.2.2.4.1 Global surgical primary cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.2.5 Dental
                              6.2.2.5.1 Global dental primary cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.2.6 Others
                              6.2.2.6.1 Global other primary cell-based therapeutics market, 2018 - 2027(USD Million)
                      6.2.3 Stem Cell & Progenitor Cell-Based Therapeutics
                          6.2.3.1 Global stem cell & progenitor cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.3.2 Autologous
                              6.2.3.2.1 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.3.3 Allogeneic
                              6.2.3.3.1 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2027(USD Million)
                          6.2.3.4 Others
                              6.2.3.4.1 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2027(USD Million)
                      6.2.4 Cell-Based Immunotherapies
                          6.2.4.1 Global cell-based immunotherapies market, 2018 - 2027(USD Million)
                      6.2.5 Gene Therapies
                          6.2.5.1 Global gene therapies market, 2018 - 2027(USD Million)
                  6.3 Tools
                      6.3.1 Global Regenerative Medicines Tools Market, 2018 - 2027(USD Million)
                  6.4 Banks
                      6.4.1 Global Banks Market For Regenerative Medicine, 2018 - 2027(USD Million)
                  6.5 Services
                      6.5.1 Global Regenerative Medicine Services Market, 2018 - 2027(USD Million)
Chapter 7 Regenerative Medicine Market: Therapeutic Category Business Analysis
                  7.1 Regenerative Medicine Market: Therapeutic Category Movement Analysis
                  7.2 Dermatology
                      7.2.1 Global Dermatological Therapeutics Market, 2018 - 2027(USD Million)
                  7.3 Musculoskeletal
                      7.3.1 Global Musculoskeletal Therapeutics Market, 2018 - 2027(USD Million)
                  7.4 Immunology & Inflammation
                      7.4.1 Global Immunology & Inflammation Therapeutics Market, 2018 - 2027(USD Million)
                  7.5 Oncology
                      7.5.1 Global Oncology Therapeutics Market, 2018 - 2027(USD Million)
                  7.6 Cardiovascular
                      7.6.1 Global Cardiovascular Therapeutics Market, 2018 - 2027(USD Million)
                  7.7 Ophthalmology
                      7.7.1 Global Ophthalmology Therapeutics Market, 2018 - 2027(USD Million)
                  7.8 Others
                      7.8.1 Global Other Therapeutics Market, 2018 - 2027(USD Million)
Chapter 8 Regenerative Medicine Market: Regional Business Analysis
                  8.1 Regenerative Medicine Market: Regional Movement Analysis
                  8.2 North America
                      8.2.1 North America Regenerative Medicine Market Estimates And Forecast, 2018 - 2027 (USD Million)
                      8.2.2 The U.S.
                          8.2.2.1 The U.S. regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.2.2.2 The U.S. regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
                      8.2.3 Canada
                          8.2.3.1 Canada regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.2.3.2 Canada regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
                  8.3 Europe
                      8.3.1 Europe Regenerative Medicine Market Estimates And Forecast, 2018 - 2027 (USD Million)
                      8.3.2 Germany
                          8.3.2.1 Germany regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.3.2.2 Germany regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
                      8.3.3 The U.K.
                          8.3.3.1 The U.K. regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.3.3.1 The U.K. regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
                  8.4 Asia-Pacific
                      8.4.1 Asia-Pacific Regenerative Medicine Market Estimates And Forecast, 2018 - 2027 (USD Million)
                      8.4.2 Japan
                          8.4.2.1 Japan regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.4.2.2 Japan regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
                      8.4.3 China
                          8.4.3.1 China regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.4.3.2 China regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
                  8.5 Latin America
                      8.5.1 Latin America regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
                      8.5.2 Brazil
                          8.5.2.1 Brazil regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.5.2.2 Brazil regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
                  8.6 MEA
                      8.6.1 MEA regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
                      8.6.2 South Africa
                          8.6.2.1 South Africa regenerative medicine market estimates and forecast, by product type, 2018 - 2027 (USD Million)
                          8.6.2.1 South Africa regenerative medicine market estimates and forecast, by therapeutic category, 2018 - 2027 (USD Million)
Chapter 9 Company Profiles
                  9.1 Company Profiles
                      9.1.1 INTEGRA LIFESCIENCES CORPORATION
                          9.1.1.1 Company overview
                          9.1.1.2 Financial performance
                          9.1.1.3 Product benchmarking
                          9.1.1.4 Strategic initiatives
                      9.1.2 ASTELLAS PHARMA INC.
                          9.1.2.1 Company overview
                          9.1.2.2 Ocata Therapeutics, Inc.
                          9.1.2.3 Financial performance
                          9.1.2.4 Product benchmarking
                          9.1.2.5 Strategic initiatives
                      9.1.3 COOK BIOTECH, INC.
                          9.1.3.1 Company overview
                          9.1.3.2 Product benchmarking
                          9.1.3.3 Strategic initiatives
                      9.1.4 BAYER AG
                          9.1.4.1 Company overview
                          9.1.4.2 BlueRock Therapeutics
                          9.1.4.3 Financial performance
                          9.1.4.4 Product benchmarking
                      9.1.5 ASTRAZENECA PLC
                          9.1.5.1 Company overview
                          9.1.5.1.1 MedImmune, LLC
                          9.1.5.2 Financial performance
                          9.1.5.3 Product benchmarking
                          9.1.5.4 Strategic initiatives
                      9.1.6 F. HOFFMANN-LA ROCHE LTD.
                          9.1.6.1 Company overview
                          9.1.6.2 Financial performance
                          9.1.6.3 Product benchmarking
                          9.1.6.4 Strategic initiatives
                      9.1.7 PFIZER, INC.
                          9.1.7.1 Company overview
                          9.1.7.2 Financial performance
                          9.1.7.3 Product benchmarking
                          9.1.7.4 Strategic initiatives
                      9.1.8 MERCK KGAA
                          9.1.8.1 Company overview
                          9.1.8.1.1 Sigma-Aldrich Co. LLC
                          9.1.8.2 Financial performance
                          9.1.8.3 Product benchmarking
                          9.1.8.4 Strategic initiatives
                      9.1.9 ABBOTT
                          9.1.9.1 Company overview
                          9.1.9.2 St. Jude Medical, Inc.
                      9.1.10 VERICEL CORPORATION
                          9.1.10.1 Company overview
                          9.1.10.2 Financial performance
                          9.1.10.3 Product benchmarking
                          9.1.10.4 Strategic initiatives
                      9.1.11 NOVARTIS AG
                          9.1.11.1 Company overview
                          9.1.11.2 Financial performance
                          9.1.11.3 Product benchmarking
                          9.1.11.4 Strategic initiatives
                      9.1.12 GLAXOSMITHKLINE PLC.
                          9.1.12.1 Company overview
                          9.1.12.2 Financial performance
                          9.1.12.3 Product benchmarking
                          9.1.12.4 Strategic initiatives
                      9.1.13 BAXTER INTERNATIONAL INC.
                          9.1.13.1 Company overview
                          9.1.13.2 Financial performance
                          9.1.13.3 Product benchmarking
                          9.1.13.4 Strategic initiatives
                      9.1.14 BOEHRINGER INGELHEIM GMBH
                          9.1.14.1 Company overview
                          9.1.14.2 Financial performance
                          9.1.14.3 Product benchmarking
                          9.1.14.4 Strategic initiatives
                      9.1.15 AMGEN INC.
                          9.1.15.1 Company overview
                          9.1.15.2 Financial performance
                          9.1.15.3 Product benchmarking
                          9.1.15.4 Strategic initiatives
                      9.1.16 CESCA THERAPEUTICS INC. / THERMOGENESIS HOLDINGS INC.
                          9.1.16.1 Company overview
                          9.1.16.2 Financial performance
                          9.1.16.3 Strategic initiatives
                      9.1.17 U.S STEM CELL, INC.
                          9.1.17.1 Company overview
                          9.1.17.2 Financial performance
                          9.1.17.3 Product benchmarking
                          9.1.17.4 Strategic initiatives
                      9.1.18 BRISTOL-MYERS SQUIBB COMPANY
                          9.1.18.1 Company overview
                          9.1.18.1.1 iPierian, Inc
                          9.1.18.2 Financial performance
                          9.1.18.3 Product benchmarking
                          9.1.18.4 Strategic initiatives
                      9.1.19 ELI LILLY AND COMPANY
                          9.1.19.1 Company overview
                          9.1.19.2 Financial performance
                          9.1.19.3 Product benchmarking
                          9.1.19.4 Strategic initiatives
                      9.1.20 NUVASIVE, INC.
                          9.1.20.1 Company overview
                          9.1.20.2 Financial performance
                          9.1.20.3 Product benchmarking
                          9.1.20.4 Strategic initiatives
                      9.1.21 ORGANOGENESIS, INC.
                          9.1.21.1 Company overview
                          9.1.21.2 NuTech
                          9.1.21.3 Financial performance
                          9.1.21.4 Product benchmarking
                          9.1.21.5 Strategic initiatives
                      9.1.22 MIMEDX GROUP, INC.
                          9.1.22.1 Company overview
                          9.1.22.2 Financial performance
                          9.1.22.3 Product benchmarking
                          9.1.22.4 Strategic initiatives
                      9.1.23 TAKARA BIO INC.
                          9.1.23.1 Company Overview
                          9.1.23.2 Financial performance
                          9.1.23.3 Product benchmarking
                          9.1.23.4 Strategic initiatives
                      9.1.24 OSIRIS THERAPEUTICS, INC.
                          9.1.24.1 Company overview
                          9.1.24.2 Smith & Nephew
                          9.1.24.3 Financial performance
                          9.1.24.4 Product benchmarking
                          9.1.24.5 Strategic initiatives
                      9.1.25 CORLINE BIOMEDICAL AB
                          9.1.25.1 Company overview
                          9.1.25.2 Financial performance
                          9.1.25.3 Product benchmarking
                          9.1.25.4 Strategic initiatives


List of Tables

Table 1 Approved primary cell-based therapeutics and stem cell & progenitor cell-based therapeutics that are considered in the revenue modeling
Table 2 Approved CAR-T & gene therapies that are considered in the revenue modeling
Table 3 List of distributors and channel partners
Table 4 Parameters taken into consideration for comparative analysis of companies operating in the market
Table 5 Parameters taken into consideration for comparative analysis of companies operating in the market
Table 6 List of key emerging companies
Table 7 Regional network mapping
Table 8 List of suppliers
Table 9 CAR-T cell resources and potential disruptions during a pandemic
Table 10 Ongoing regenerative medicine clinical trials to treat COVID-19 & related complications, as of April 14, 2020
Table 11 Various approaches in regenerative medicine for dermatological use
Table 12 Predicted prevalence of Osteoporosis and Low Bone Mass for 2010 & 2030
Table 13 Prevalence of ophthalmic diseases in the U.S
Table 14 Global burden of neurological diseases: Projected number of Disability Adjusted Life Years (DALYs) for neurological disorders
Table 15 UK: National action in regenerative medicine
Table 16 UK: Funds for regenerative medicine research: 2012 - 2017 (in USD million)
Table 17 Main monographs published in china
Table 18 Latin America: Current initiatives and opportunities
Table 19 North America regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 20 North America regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 21 North America primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 22 North America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 23 North America regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 24 The U.S. regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 25 The U.S. regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 26 The U.S. primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 27 The U.S. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 28 The U.S. regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 29 Canada regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 30 Canada regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 31 Canada primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 32 Canada stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 33 Canada regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 34 Europe regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 35 Europe regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 36 Europe primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 37 Europe stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 38 Europe regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 39 Germany regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 40 Germany regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 41 Germany primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 42 Germany stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 43 Germany regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 44 The U.K. regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 45 The U.K. regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 46 The U.K. primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 47 The U.K. stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 48 The U.K.regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 49 Asia Pacific regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 50 Asia Pacific regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 51 Asia Pacific primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 52 Asia Pacific stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 53 Asia Pacific regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 54 China regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 55 China regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 56 China primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 57 China stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 58 China regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 59 Japan regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 60 Japan regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 61 Japan primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 62 Japan stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 63 Japan regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 64 Latin America regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 65 Latin America regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 66 Latin America primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 67 Latin America stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 68 Latin America regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 69 Brazil regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 70 Brazil regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 71 Brazil primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 72 Brazil stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 73 Brazil regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 74 MEA regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 75 MEA regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 76 MEA primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 77 MEA stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 78 MEA regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)
Table 79 South Africa regenerative medicines market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 80 South Africa regenerative therapeutics market estimates& forecasts, by product, 2018 - 2027 (USD Million)
Table 81 South Africa primary cell-based therapeutics market estimates& forecasts, by disease category, 2018 - 2027 (USD Million)
Table 82 South Africa stem cell & progenitor cell-based therapeutics market estimates& forecasts, by source type, 2018 - 2027 (USD Million)
Table 83 South Africa regenerative medicine market estimates& forecasts, by therapeutic category, 2018 - 2027 (USD Million)


List of Figures

Fig. 1 Market segmentation & scope
Fig. 2 Regenerative medicine market snapshot, USD Million, 2020
Fig. 3 Market research process
Fig. 4 Information procurement
Fig. 5 Industry pyramid analysis
Fig. 6 Industry pyramid analysis
Fig. 7 Market research approaches
Fig. 8 Value-chain-based sizing & forecasting
Fig. 9 QFD model assessment
Fig. 10 Industry pyramid analysis
Fig. 11 Commodity flow analysis for historic and base year estimates
Fig. 12 Commodity flow analysis for forecast analysis
Fig. 13 Initiatives by Vericel Corporation to sustain market and boost revenue through its approved therapeutics
Fig. 14 Regenerative medicines market: Ancillary market
Fig. 15 Regenerative medicine market driver impact
Fig. 16 Some major industry sponsors of CAR T cell clinical trials, as of September 2019
Fig. 17 Gene therapies in clinical trials at the end of 2019 globally
Fig. 18 Number of ongoing clinical trials, 2017 & 2018
Fig. 19 Global financings for regenerative medicine, 2018
Fig. 20 Prevalence of chronic diseases in the U.S.
Fig. 21 Regenerative medicine market restraint impact
Fig. 22 Challenges in gene therapy arena by degree of difficulty to overcome
Fig. 23 Penetration & growth prospect mapping for therapeutic category, 2020
Fig. 24 Troubleshooting the challenges of implementing new reimbursement models pertaining to regenerative medicine
Fig. 25 Reimbursement models pertaining to regenerative medicine
Fig. 26 Operational entities associated with Alliance for regenerative medicine: Technology overview
Fig. 27 Inpatient vs. outpatient costs associated with CAR-T cell therapy
Fig. 28 Regenerative medicine: Market influencers
Fig. 29 SWOT analysis, by factor (Political & legal, economic, and technological)
Fig. 30 Porter’s Five Forces Analysis
Fig. 31 Strategy mapping
Fig. 32 Total M&A upfront payments in regenerative medicine space, by year
Fig. 33 Regenerative medicines market: Business model
Fig. 34 Registered cell therapy contract manufacturing organization (CMO) locations in the EU, according to EudraGMDP, May 2018
Fig. 35 Marketing channels
Fig. 36 Recent developments by key market participants
Fig. 37 Impact analysis of strategic moves employed by key market participants
Fig. 38 Company/competition categorization
Fig. 39 Key customers
Fig. 40 Key company market position analysis, 2020
Fig. 41 Top regional players: Regenerative medicine market
Fig. 42 Regenerative medicine market: Competitive dashboard analysis
Fig. 43 Regenerative medicine market: Product outlook and key takeaways
Fig. 44 Regenerative medicine market: Product movement analysis (USD Million)
Fig. 45 Global regenerative medicine therapeutics market, 2018 - 2027 (USD Million)
Fig. 46 Global primary cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 47 Global dermatology primary cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 48 Global musculoskeletal primary cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 49 Global surgical primary cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 50 Global dental primary cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 51 Global other primary cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 52 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 53 Global autologous stem cell & progenitor cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 54 Global allogeneic stem cell & progenitor cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 55 Global other stem cell & progenitor cell-based therapeutics market, 2018 - 2027 (USD Million)
Fig. 56 Global cell-based immunotherapies market, 2018 - 2027 (USD Million)
Fig. 57 Global gene therapies market, 2018 - 2027 (USD Million)
Fig. 58 Global regenerative medicines tools, 2018 - 2027 (USD Million)
Fig. 59 Global banks market for regenerative medicine, 2018 - 2027 (USD Million)
Fig. 60 Global regenerative medicine services market, 2018 - 2027 (USD Million)
Fig. 61 Regenerative medicine market: Therapeutic category outlook and key takeaways
Fig. 62 Regenerative medicine market: Therapeutic category movement analysis (USD Million)
Fig. 63 Global dermatological therapeutics category market, 2018 - 2027 (USD Million)
Fig. 64 Global musculoskeletal therapeutics category market, 2018 - 2027 (USD Million)
Fig. 65 Global immunology & inflammation therapeutics category market, 2018 - 2027 (USD Million)
Fig. 66 Global oncology therapeutics category market, 2018 - 2027 (USD Million)
Fig. 67 Global cardiovascular therapeutics category market, 2018 - 2027 (USD Million)
Fig. 68 Global ophthalmology therapeutics market, 2018 - 2027 (USD Million)
Fig. 69 Global other therapeutics category market, 2018 - 2027 (USD Million)
Fig. 70 Regional outlook and key takeaways
Fig. 71 Regenerative medicine market: Regional movement analysis
Fig. 72 North America regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 73 The U.S. regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 74 Canada regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 75 Europe regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 76 Germany regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 77 The U.K. regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 78 Asia-Pacific regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 79 Japan regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 80 China regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 81 Latin America regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 82 Brazil regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 83 MEA regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)
Fig. 84 South Africa regenerative medicine market estimates and forecast, 2018 - 2027 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon gvr sidebar D&B icon gvr sidebar

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.